Research on heart failure and its treatment. Covers light exposure, heart-in-a-dish models, microRNA therapy, and surgical interventions.
A new analysis of health records from 2016 to 2020 found that takotsubo cardiomyopathy, also known as broken heart syndrome, is associated with a high risk of death and complications. Researchers highlight the importance of careful monitoring and prompt treatment for patients with this condition.
This observational study of the MIMIC-IV database identifies Charlson Comorbidity Index (CCI), red blood cell count (RBC), and red cell distribution width (RDW) as significant predictors of 90-day readmission in heart failure patients. RBC and RDW show linear correlation, while CCI and age display nonlinear correlation.
A multicenter retrospective study compared perioperative renal function in heart transplantation and LVAD implantation patients with pre-existing renal dysfunction, finding improved outcomes for those receiving the new device. The results suggest that LVAD implantation is a better choice for these patients.
A cohort study of US veterans found that depression is associated with a higher hazard of incident heart failure after controlling for demographic and cardiovascular risk factors. Depression remains consistent as a risk factor even in low-risk cohorts.
A new Vanderbilt University Medical Center-led study found US veterans with depression had a 14% higher risk of heart failure, even after adjusting for traditional risk factors. The study suggests that screening and treating depression may help prevent future heart failure in patients.
Researchers at University of East Anglia developed 4D flow MRI scan to diagnose aortic stenosis more accurately and reliably than current ultrasound techniques. The technology offers more accurate measurements of blood flow through heart valves, leading to better prediction of when patients need surgery.
Dr. Kenneth Rosenfield is a distinguished interventional cardiologist recognized for his seminal work in endovascular therapy and pioneering innovative techniques. He has made significant contributions to the field of vascular medicine, including the development of self-expanding stents and drug-coated balloons.
A study of over a million people found that shingles vaccination lowers the risk of cardiovascular events, including stroke and coronary heart disease, by up to 26%. The vaccine's protective effect lasts for up to eight years, with strongest benefits in younger people and men.
A new analysis shows hospitals participating in the American Heart Association’s IMPLEMENT-HF initiative significantly improved adherence to guideline-directed medical therapy for patients hospitalized with HFrEF. The initiative boosted use of lifesaving medications and integrated health-related social needs assessments into routine care.
A new MRI technique measures a person's 'functional age' of their heart, revealing how unhealthy lifestyles add years to their heart's aging process. This method has the potential to transform heart disease diagnosis and offer a lifeline to millions by catching problems early.
Researchers analyzed medical claims data to identify increased risks of heart failure, atrial fibrillation, and fractures among breast cancer survivors. The study highlights the importance of preventive care for these individuals.
The American Heart Association has awarded $1M to research the link between cardiovascular risk reduction and GLP-1 use. The studies aim to identify predictors of cardiovascular risk reduction among individuals with obesity and cardiovascular disease taking GLP-1 medications, enabling more precise and effective care.
Pediatric hearts fail due to acquired and genetic disorders or congenital heart disease, requiring mechanical circulatory support (MCS) devices. However, adult devices are often used off-label in pediatric patients, deterring innovation and limiting access to life-saving technology.
The first-ever Cardiogenic Shock Academy features a simulation lab, providing hands-on training for treating patients in cardiogenic shock. More than 160 healthcare practitioners from around the world attended the academy, which aimed to address the lack of conclusive research for managing CS.
Researchers developed a new therapy that can be injected intravenously right after a heart attack to promote healing and prevent heart failure. The therapy both prompts the immune system to encourage tissue repair and promotes survival of heart muscle cells after a heart attack, showing effectiveness up to five weeks after injection.
Scientists developed an injectable therapy that protects the heart from damage after a heart attack by blocking the interaction between two proteins, Keap1 and Nrf2. The study showed decreased inflammation, cell death, and improved cardiac function in animal models.
The Mount Sinai Fuster Heart Hospital cardiology faculty practice has received the 2024 Human Experience Pinnacle of Excellence Award from Press Ganey, a leading patient experience organization. The hospital ranks among the top 5% of healthcare providers in delivering patient experience over three years.
A noise-adapted AI model using lead I ECGs estimated heart failure risk with high accuracy, suggesting a potential strategy for early detection. The study's results highlight the promise of wearable and portable ECG devices in identifying at-risk patients.
A new study finds that a remote patient monitoring program reduced hospitalizations by 59% among high-risk patients, even after they mailed back their devices. The program uses digital health devices and clinician support to monitor vital signs and symptoms.
Researchers discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective treatment. Restoring this mechanism prevents progression of HFpEF and alleviates lipid overload in heart cells, providing molecular evidence for a promising therapeutic...
A new study from Karolinska Institutet found that people with a certain heart valve abnormality are at increased risk of severe heart rhythm disorders even after successful valve surgery. The condition is more common in women and younger patients, and can lead to sudden cardiac arrest.
Stephan Windecker, a world-renowned cardiologist, will be honored with the TCT 2025 Career Achievement Award for his extraordinary contributions to interventional cardiology. His extensive research has shaped clinical practice worldwide and influenced the future of cardiovascular medicine.
Researchers developed an injectable hydrogel containing fish swim bladder components to repair damaged heart tissue, showing enhanced cardiac cell adhesion and stretching. The treatment also promoted new blood vessel formation and reduced inflammation in a rat model of ischemic heart failure.
A recent study published in the International Journal of Cardiology analyzed data from multiple clinical trials to assess the therapeutic impact of pulmonary artery denervation (PADN) on pulmonary hypertension patients. PADN showed significant reductions in mean right atrial pressure, mean pulmonary artery pressure, and pulmonary vascu...
A large long-term study found a significant association between hearing loss and increased risk of developing heart failure. The psychological distress caused by hearing impairment played a key role in this observed association, with socially isolated individuals and those experiencing anxiety and depression facing a heightened risk.
A study of nearly 30,000 adults found that heart failure is associated with a significant decrease in cognition at diagnosis and rapid decline over time. Adults with heart failure reach the threshold for meaningful decline in global cognition nearly six years earlier than those without it.
The device uses AI technology to detect potential heart problems and provides real-time health insights. It has multiple points touching the skin near the heart, allowing for more accurate tracking even during movement.
The SUMMIT trial shows tirzepatide reduces the risk of cardiovascular death or worsening heart failure in patients with obesity, chronic kidney disease, and heart failure, while improving kidney function. Researchers found significant improvements in both patient groups with and without chronic kidney disease.
A large-scale study found that limiting fluid intake in patients with stable heart failure has no health benefits and may even cause increased thirst. Conversely, drinking more fluids without restriction did not lead to any negative outcomes, suggesting that fluid restrictions are unnecessary for these patients.
A minimally invasive procedure using a clip to repair the tricuspid valve significantly reduced symptom severity and decreased recurrent hospitalization for heart failure. The study found a 28% reduction in hospitalizations at two years, with improved safety and effectiveness compared to medical therapy alone.
A new mobile integrated health program delivered in-home visits from paramedic teams to people with heart failure did not significantly reduce hospital readmissions or improve health status compared to standard follow-up phone calls. However, the study found that women and younger patients may benefit more from this intervention.
The Finerenone Trial found that sudden death was the primary cause of higher cardiovascular mortality in patients with heart failure and mild or preserved ejection fractions. The study suggests that finerenone may not significantly impact cardiovascular mortality, but its effects on overall mortality are unclear.
A study found that intravenous iron supplementation resulted in a 20% lower risk of cardiovascular death or first heart failure hospitalization, as well as improved symptoms and quality of life. The benefits were most pronounced in the first year after treatment, suggesting a meaningful association between iron dosage and outcomes.
A large randomized controlled trial found no significant difference in health status between patients with restricted and unrestricted fluid intake. Despite this, patients on fluid restriction reported more thirst and had lower overall health scores at baseline compared to those with liberal fluid intake.
Early IABP use did not improve 60-day survival or transition patients to long-term treatment compared to standard medical care. The trial found that the device offered no additional benefit, leading to its early termination.
Ferric carboxymaltose did not significantly reduce time to first heart failure hospitalization or cardiovascular death in patients with heart failure and iron deficiency. The treatment also did not reduce total number of heart failure hospitalizations compared to placebo.
A study presented at the American College of Cardiology's Annual Scientific Session found that dapagliflozin significantly reduced the rate of worsening heart failure in elderly patients with heart failure undergoing transcatheter aortic valve replacement. The trial, called DapaTAVI, enrolled 1,257 patients and showed a 28% lower rate ...
A study published in JAMA Cardiology found that finerenone was effective in treating heart failure, regardless of the presence of atrial fibrillation. New-onset atrial fibrillation was linked to a substantially increased risk of adverse outcomes.
Researchers from Emory University are using the International Space Station to study cardiac cells and accelerate the development of cell-based regenerative therapies. The team's findings have led to multiple peer-reviewed publications and could significantly advance methods to produce cardiac cells for heart disease treatment.
The American Heart Association has launched a new certification program for hospitals dedicated to optimizing heart failure treatment, reducing readmissions. The Heart Failure Center Certification aims to enhance patient outcomes and promote evidence-based treatments.
Researchers found that gasdermin D promotes atrial arrhythmogenesis by facilitating the formation of pores in cell membranes and releasing cytokines. A mitochondrial-targeted therapy approach may prevent AF triggering, positioning gasdermin D as a promising therapeutic target.
People with heart failure who can travel outside their home without assistance are less likely to be hospitalized or die within a year. Life-space mobility, a measure of how far patients move in their communities, is a reliable marker of risk for adverse outcomes in chronic diseases.
TCT 2025 will take place October 25-28, 2025, at the Moscone Center in San Francisco, California. The event will feature acute interventions, breakthrough technologies, and cutting-edge research driving the next era of cardiovascular care.
A study found that women who underwent bilateral oophorectomy were more likely to develop heart failure later in life. The researchers suggest that early menopause may be a contributing factor to this increased risk, and recommend closer cardiovascular monitoring for women contemplating the procedure.
Researchers at the University of Virginia Health System have developed a computational tool called LogiRx that can predict how drugs will affect biological processes in the body. The tool has demonstrated its potential by identifying a promising candidate to prevent heart failure, a leading cause of death worldwide.
A recent study published in the European Journal of Preventive Cardiology found that older patients with heart failure who exercised regularly before hospitalization had better physical function and lower mortality. Regular exercise was linked to greater grip strength, higher gait speeds, and improved overall health outcomes.
A new study from Karolinska Institutet found that patients with heart failure who stop taking medications like RASi, ARNi, or MRA have a higher risk of heart-related death or hospitalization. Despite improved symptoms and pump function, continued medication is crucial to prevent complications.
Researchers have discovered a new way to stimulate cardiomyocyte proliferation, offering promising results in both human cardiac slices and live animals. This innovative approach targets calcium signaling pathways, potentially transforming the treatment landscape for patients suffering from heart failure.
Josep Rodés-Cabau takes over as Editor-in-Chief of Structural Heart: The Journal of the Heart Team, following Anthony N. DeMaria's retirement. Dr. Rodés-Cabau is a world-renowned expert in structural heart disease with extensive research and academic experience.
A recent study by Professor Mamas highlights the significant risk of cardiovascular diseases (CVD) in patients with cancer, particularly in aging populations. The review emphasizes the need for early diagnosis and regular monitoring to improve quality of life.
A new study published in the European Journal of Preventive Cardiology found that a type of diabetes medication called SGLT2 inhibitors can significantly lower the risk of heart failure and hospital visits related to heart failure in cancer patients. The benefits were particularly promising for breast cancer patients receiving anthracy...
The project aims to improve the quality of life for patients with end-stage heart failure and their caregivers through a nurse-led intervention. The study will also track hospitalization rates, patient well-being, and gain a better understanding of end-of-life care.
Preoperative anemia is a recognized risk factor for adverse outcomes in CABG, but it does not affect the long-term survival advantage associated with CABG. This study provides evidence that surgical intervention can still be beneficial for ICM patients despite preoperative anemia.
A retrospective cohort study from the University of Ottawa and Manitoba found Canadians with hypertension whose preferred language was spoken by their doctor were 36% less likely to have a major adverse cardiovascular event. Patients with language-accessible care had a 28% lower risk of death compared to those without such access.
Johnson & Johnson MedTech is celebrating the inaugural National Heart Recovery Awareness Day to raise awareness of heart health and innovative medical technology. The company's Impella platform has been used to treat over 330,000 patients globally, enabling patients to recover their native heart and improve their quality of life.
A new medication approved to treat type 2 diabetes and kidney disease also significantly reduces the risk of heart attacks and strokes among these patients. Sotagliflozin, a sodium-glucose cotransporter inhibitor, blocks proteins that help control blood sugar levels and has been shown to reduce cardiovascular events by 23%.
A study published in Nature Cardiovascular Research found that tricaprin improved long-term survival and recovery from heart failure in patients with triglyceride deposit cardiomyovasculopathy. The supplement reversed structural changes and improved heart muscle function, leading to higher survival rates compared to controls.
A new mechanical heart pump, BrioVAD, is being tested against the current standard, HeartMate 3, in a national study. The trial aims to enroll 780 participants with advanced heart failure and will compare the two devices head-to-head.
The article proposes clear career paths and standardized training pathways in interventional heart failure, aiming to enable specialists to drive innovation and improve outcomes. It highlights the need for a formalized approach to training and career development in this field.
A new Northwestern Medicine study reveals that macrophages in newborns use a process called efferocytosis to produce thromboxane, which triggers the production of a bioactive lipid that signals heart muscle cells to divide and regenerate. This process is less effective in adults, leading to scar-tissue buildup and often heart failure.